LDLR and hypertriglyceridemia: As expected, our retrospective analysis shows that volanesorsen reduced plasma TGs in homozygous APOE3 or APOE4 (or a combinations of those isoforms) hypertriglyceridemia patients most likely by facilitating TRL clearance via LDLR and LRP1 (5).